CPX CORP
10-Q, 2000-02-14
LABORATORY APPARATUS & FURNITURE
Previous: SHOPKO STORES INC, SC 13G, 2000-02-14
Next: BARRA INC /CA, 10-Q, 2000-02-14



                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                 --------------

                                   FORM 10-Q

[X]     QUARTERLY  REPORT  PURSUANT  TO SECTION  13 OR 15(d)  OF THE  SECURITIES
        EXCHANGE ACT OF 1934

                For the quarterly period ended December 31, 1999

                                       OR

[ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
        SECURITIES EXCHANGE ACT OF 1934

        For the transition period from ___________ to ___________.

                        Commission File number: 0-19472

                                   CPX Corp.
             (Exact name of registrant as specified in its charter)

            Delaware                                          94-3087971
(State or other jurisdiction of                            (I.R.S. Employer
 incorporation or organization)                             Identification No.)


                        150 East 52nd Street 21st Floor,
                            New York, New York 10022
        (Address of registrant's principal executive offices) (Zip Code)

                                 (877) 431-2942
              (Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

                                 Yes [x] No [ ]


                                                Outstanding at February 14, 2000
Common Stock, $0.001 par value                              14,633,985



<PAGE>
                                     INDEX



        Page No.
PART I  FINANCIAL INFORMATION

Item 1. Financial Statements:

        Condensed Consolidated Balance Sheets as of
        December 31, 1999 (unaudited) and March 31, 1999                3

        Condensed Consolidated Statements of Operations for the
        Three Months ended December 31, 1999 and 1998 (unaudited)       4

        Condensed Consolidated Statements of Operations for the
        Nine Months ended December 31, 1999 and 1998 (unaudited)        5

        Condensed Consolidated Statements of Cash Flows for the
        Nine months ended December 31, 1999 and 1998 (unaudited)        6

        Notes to Condensed Financial Statements                         7

Item 2. Management's Discussion and Analysis of Financial
        Condition and Results of Operations                             9

PART II OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K                               10

Signatures                                                             11

<PAGE>
PART I: FINANCIAL INFORMATION

ITEM 1.  FINANCIAL STATEMENTS


                           CPX CORP. AND SUBSIDIARIES
                     CONDENSED CONSOLIDATED BALANCE SHEETS

                DECEMBER 31, 1999 (Unaudited) AND MARCH 31, 1999

<TABLE>
<CAPTION>
                                     ASSETS
<S>                                                          <C>               <C>

                                                                December 31,      March 31,
                                                                    1999            1999
                                                                (Unaudited)

        Cash and cash equivalents .........................   $   1,263,000    $  17,061,000
        Accounts receivable, net of allowance for
                doubtful accounts of $0 & $13,491 .........            --            214,000
        Marketable securities .............................            --          1,368,000
        Prepaid expenses ..................................            --            222,000
        Equipment .........................................            --              3,000
        Investment in and receivable from subsidiary ......            --            370,000
                                                              -------------    -------------
Total assets ..............................................   $   1,263,000    $  19,238,000
                                                              =============    =============

                      LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
        Accounts payable ..................................   $        --      $       6,000
        Pre-petition debt .................................            --         12,683,000
        Other liabilities .................................            --          1,521,000
                                                              -------------    -------------
Total liabilities .........................................            --         14,210,000

Stockholders' equity:
        Common stock, $.001 par value; 25,000,000
                shares authorized; 14,633,985 shares issued
                and outstanding ...........................          15,000           15,000
        Additional paid-in capital ........................     165,271,000      169,908,000
        Accumulated deficit ...............................    (164,023,000)    (164,895,000)
                                                              -------------    -------------
Total stockholders' equity ................................       1,263,000        5,028,000
                                                              -------------    -------------
Total liabilities and stockholders' equity ................   $   1,263,000    $  19,238,000
                                                              =============    =============
</TABLE>

          See accompanying notes to consolidated financial statements.

<PAGE>
                           CPX CORP. AND SUBSIDIARIES
                     CONSOLIDATED STATEMENTS OF OPERATIONS

                 THREE MONTHS ENDED DECEMBER 31, 1999 AND 1998
                                  (Unaudited)
<TABLE>
<CAPTION>
                                                           Three months ended December 31,

                                                                 1999            1998
<S>                                                         <C>             <C>
Product sales ...........................................   $       --      $  3,255,000
                                                            ------------    ------------
Total revenues ..........................................           --         3,255,000

Costs and expenses:
        Cost of product sales ...........................           --         1,435,000
        Selling, general and administrative .............         48,000       1,897,000
                                                            ------------    ------------
                Total costs and expenses ................         48,000       3,332,000
                                                            ------------    ------------
                       Loss from operations .............        (48,000)        (77,000)

Other income (expense):
        Interest income .................................         29,000            --
        Other, net ......................................         13,000      (9,085,000)
                                                            ------------    ------------
                Total other income/(expense) ............         42,000      (9,085,000)
                                                            ------------    ------------
                        Net income/(loss) ...............   $     (6,000)   $ (9,162,000)
                                                            ============    ============


Net income/(loss) per share - basic and diluted .........   $       (.00)   $       (.63)


Weighted average number of common shares
    outstanding during the period - basic and diluted         14,634,000      14,621,000
</TABLE>

          See accompanying notes to consolidated financial statements.
<PAGE>

                           CPX CORP. AND SUBSIDIARIES
                     CONSOLIDATED STATEMENTS OF OPERATIONS

                  NINE MONTHS ENDED DECEMBER 31, 1999 AND 1998
                                  (Unaudited)
<TABLE>
<CAPTION>
                                                           Nine months ended December 31,

                                                                1999            1998
<S>                                                         <C>             <C>
Product sales ...........................................   $       --      $  9,912,000
                                                            ------------    ------------

Total revenues ..........................................           --         9,912,000

Costs and expenses:
        Cost of product sales ...........................           --        12,209,000
        Research and development ........................           --         6,030,000
        Selling, general and administrative .............        873,000       8,803,000
                                                            ------------    ------------
                Total costs and expenses ................        873,000      27,042,000
                                                            ------------    ------------
                        Loss from operations ............       (873,000)    (17,130,000)

Other income (expense):
        Interest income .................................        197,000         350,000
        Interest expense ................................       (117,000)         (6,000)
        Legal settlement ................................      1,400,000            --
        Administrative reserve ..........................        250,000            --
        Other, net ......................................         15,000     (10,364,000)
                                                            ------------    ------------
                Total other income/(expense) ............      1,745,000     (10,020,000)
                                                            ------------    ------------
                        Net income/(loss) ...............   $    872,000    $(27,150,000)
                                                            ============    ============


Net income/(loss) per share - basic and diluted..........   $        .06    $      (1.86)


Weighted average number of common shares
    outstanding during the period - basic and diluted....     14,634,000      14,621,000
</TABLE>

          See accompanying notes to consolidated financial statements.
<PAGE>
                           CPX CORP. AND SUBSIDIARIES
                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

                  NINE MONTHS ENDED DECEMBER 31, 1999 AND 1998
                                  (Unaudited)

                                               Nine months ended December 31,

                                                    1999            1998

Net cash used in operating activities .......   $   (217,000)   $(20,880,000)
                                                ------------    ------------

Cash flows from investing activities:
Proceeds from sale of subsidiary ............        370,000            --
Proceeds from sale of equipment .............          1,000       5,046,000
    Proceeds from sales and maturities
        of securities available for sale ....           --         7,746,000
Change in restricted cash equivalents .......           --         9,220,000
                                                ------------    ------------
    Net cash provided by investing activities        371,000      22,012,000
                                                ------------    ------------

Cash flows from financing activities:

    Principal payments on long-term debt ....           --          (313,000)
    Payments on pre petition debt, net ......    (11,315,000)           --
    Distribution to shareholders ............     (4,637,000)           --
    Other ...................................           --        (1,410,000)
                                                ------------    ------------
    Net cash used in financing activities ...    (15,952,000)     (1,723,000)
                                                ------------    ------------
Net decrease in cash and cash equivalents ...    (15,798,000)       (591,000)

Cash and cash equivalents:
    Beginning of period .....................     17,061,000      12,464,000
                                                ------------    ------------
    End of period ...........................   $  1,263,000    $ 11,873,000
                                                ============    ============

          See accompanying notes to consolidated financial statements.
<PAGE>

                           CPX CORP. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                      NINE MONTHS ENDED DECEMBER 31, 1999
                                  (Unaudited)

1.      Basis of Presentation

     The accompanying  unaudited  consolidated financial statements of CPX Corp.
(the  "Company,"   formerly  named  Cellpro   Corporation)  should  be  read  in
conjunction with the audited  financial  statements and notes there to contained
in the  Company's  Report on Form 8-K for the year ended March 31, 1999.  In the
opinion of management,  all adjustments necessary for a fair presentation of the
interim operating  results are reflected herein.  Results for the three and nine
months ended  December 31, 1999 are not  necessarily  indicative  of the results
that may be expected  either for any other  quarter in the year ending March 31,
2000 or for the entire year ending March 31, 2000.

2.      Operations

     The Company  currently  has no operating  business.  Management is pursuing
various strategic  alternatives  which include the possible use of the Company's
remaining net assets to acquire, merge, consolidate or otherwise combine with an
operating business or businesses;  however,  there is no assurance that any such
alternatives will occur.

3.      Bankruptcy Plan and Distribution of Funds

     On October 28, 1998, CellPro,  Incorporated  ("CellPro," the former name of
the Company)  filed for  bankruptcy  protection  under  Chapter 11 of the United
States  Bankruptcy Code, Case No. 98-13604 in the United States Bankruptcy Court
for the Western District of Washington,  Judge Karen  Overstreet  presiding (the
"Bankruptcy  Court").  On May 21,  1999 the  Bankruptcy  Court  issued  an order
confirming CellPro's Second Amended Plan of Reorganization (the "Plan") dated as
of May 10, 1999. The effective date of the Plan occurred on June 1, 1999.

4.      Net Income Loss Per Share

     Presentation  of basic  earnings  per share  ("EPS") and diluted EPS on the
face of the consolidated  statements of operations is required for entities with
complex capital structures. Basic EPS is based on the weighted average number of
common  shares  outstanding  during  the  period.  Diluted  EPS is  based on the
potential dilution that would occur on exercise or conversion of securities into
common stock using the treasury stock method.  However,  potential common shares
that are  considered to be  anti-dilutive  are excluded from the  computation of
diluted EPS. Since the Company had a loss from operations for the three and nine
months ended  December 31, 1998,  inclusion of potential  common shares would be
anti-dilutive. Accordingly, such potential common shares have been excluded from
the  computation  of diluted EPS resulting in the same amount for both basic and
diluted  EPS.  Specifically,  options to acquire  2.7  million  shares have been
excluded from the calculation of diluted EPS for the quarters ended December 31,
1998.  Outstanding stock options could potentially dilute EPS in future periods.
For the quarters ending December 31, 1999, there were no options outstanding and
thus no potential dilutive effect.

<PAGE>
5.      Comprehensive Income

     In June 1997, the Financial  Accounting Standards Board issued Statement of
Financial Accounting Standards No. 130, "Reporting  Comprehensive Income" ("SFAS
130"). The Company  implemented SFAS 130 during the quarter ended June 30, 1998.
Comprehensive  income includes net  income/(loss)  as shown in the  consolidated
statement  of  operations  adjusted  by certain  amounts  that are  included  in
stockholders'  equity  accounts.  Net  unrealized  gains or losses on securities
available for sale and foreign currency translation  adjustments  resulting from
the consolidation of foreign operations are the only two adjustments to net loss
to  arrive  at  the  Company's   comprehensive   loss.  The  table  below  shows
comprehensive loss for the periods presented:
<TABLE>
<CAPTION>

                                         December 31, 1999               December 31, 1998

                                    Three months     Nine months    Three months     Nine months
<S>                                 <C>             <C>             <C>             <C>
Net Income/(loss) ...............   $     (6,000)   $    872,000    $ (9,162,000)   $(27,150,000)
Foreign currency translation ....          --              --              --             21,000
Net unrealized gain (loss) on
 securities available for sale...          --              --              --             (6,000)
                                    ------------    ------------    ------------    ------------
Comprehensive Income/(loss) .....   $     (6,000)   $    872,000    $ (9,162,000)   $(27,135,000)
                                    ============    ============    ============    ============
</TABLE>
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

OVERVIEW

     The Company filed a voluntary petition for reorganization  under Chapter 11
of the United  States  Bankruptcy  Code on October  28,  1998,  and the  Company
commenced  liquidation  shortly  thereafter.  The Company announced in June 1999
that it has  changed  its name to CPX Corp.  from  Cellpro,  Incorporated.  Also
during  June  1999 the  Company  distributed  funds  to  equity  holders  and in
September  1999  made  final  distribution  of funds to  equity  holders  having
received the $1.4 million proceeds from a legal settlement.

     Except for disclosures that report the Company's  historical  results,  the
statements  set forth in this  section are  forward-looking  statements.  Actual
results  may differ  materially  from  those  projected  in the  forward-looking
statements.  Additional  information  concerning  factor  that may cause  actual
results to differ  materially from those in the  forward-looking  statements are
set forth in the section entitled  "Investment  Considerations" in the Company's
Annual Report on Form 10-K for the fiscal year ended March 31, 1998," and in the
Company's other filings with the Securities and Exchange Commission. Readers are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof.  The Company  assumes no  obligation to update
any such  forward-  looking  statements  or  comment on the  reasons  why actual
results may differ therefrom.


LIQUIDITY AND CAPITAL RESOURCES

     The Company's cash and cash equivalents totaled approximately $1,263,000 as
of  December  31,  1999 and  approximately  $17,061,000  as of March  31,  1999.
Elimination of virtually all  liabilities,  loss on  operations,  and payment to
stockholders combined to account for the decrease in cash. At December 31, 1999,
the Company had no liabilities and  consequently  the Company's  working capital
balance was approximately $1,263,000.  While the Company seeks an acquisition or
other business combination,  management believes its cash position is sufficient
to cover  administrative  expenses and current  obligations  for the foreseeable
future.  There can be no  assurance  that the Company  will be able to locate or
purchase an additional  business,  or that any such business will be profitable.
In order to finance an  acquisition,  the  Company  may be  required to incur or
assume indebtedness or issue securities.

RESULTS OF OPERATIONS

     Income/(loss)  from operations for the three and nine months ended December
31, 1999 and 1998 were ($6,000) and $872,000 and ($9,162,000) and ($27,150,000),
respectively.  The income  during the three and nine months  ended  December 31,
1999  resulted  primarily  from no costs of  production,  interest  income and a
favorable legal  settlement.  Proceeds from the legal settlement were recognized
in income and then distributed to shareholders as return of capital.

     Costs and expenses of $873,000 for the nine months ended  December 31, 1999
were down significantly from approximately $27,042,000 for the nine months ended
December 31, 1998. The decrease was due to lower administrative demands, no cost
of  production,  and no research  and  development  expense  since there were no
operating activities. Almost all of the $873,000 costs and expenses for the nine
months ended December 31, 1999 were incurred as a result of the restructuring of
the Company and the legal settlement.

<PAGE>
PART II. OTHER INFORMATION


ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

         (a)  Exhibits

              Exhibit 27 - Financial Data Schedule (filed as part of the
              electronic filing only).

         (b)  Reports on Form 8-K

              The Registrant filed the following current report on Form 8-K
              during the quarter for which this report is filed.

              None

<PAGE>
                                  SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.

                                  CPX, CORP. (Registrant)





                                  By /s/Warren G. Lichtenstein
                                     Warren G. Lichtenstein,
                                     President


                                  By /s/Brian Lorber
                                     Brian Lorber,
                                     Secretary/Treasurer


Date:  February 14, 2000


<TABLE> <S> <C>


<ARTICLE>                     5

<CIK>                         0000878377
<NAME>                        CPX Corp.
<MULTIPLIER>                                   1,000
<CURRENCY>                                     DOLLARS

<S>                                            <C>
<PERIOD-TYPE>                                  9-MOS
<FISCAL-YEAR-END>                              MAR-31-2000
<PERIOD-START>                                 APR-1-1999
<PERIOD-END>                                   DEC-31-1999
<EXCHANGE-RATE>                                1
<CASH>                                         1,263
<SECURITIES>                                       0
<RECEIVABLES>                                      0
<ALLOWANCES>                                       0
<INVENTORY>                                        0
<CURRENT-ASSETS>                                   0
<PP&E>                                             0
<DEPRECIATION>                                     0
<TOTAL-ASSETS>                                 1,263
<CURRENT-LIABILITIES>                              0
<BONDS>                                            0
                              0
                                        0
<COMMON>                                          15
<OTHER-SE>                                     1,263
<TOTAL-LIABILITY-AND-EQUITY>                   1,263
<SALES>                                            0
<TOTAL-REVENUES>                                   0
<CGS>                                              0
<TOTAL-COSTS>                                    873
<OTHER-EXPENSES>                                   0
<LOSS-PROVISION>                                   0
<INTEREST-EXPENSE>                                 0
<INCOME-PRETAX>                                  872
<INCOME-TAX>                                       0
<INCOME-CONTINUING>                              872
<DISCONTINUED>                                     0
<EXTRAORDINARY>                                    0
<CHANGES>                                          0
<NET-INCOME>                                     872
<EPS-BASIC>                                    .06
<EPS-DILUTED>                                    .06



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission